Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
30 October 2013Website:
http://www.veracyte.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
VCYT Latest News
In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and.
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay o.
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 1(current)
What type of business is Veracyte?
Veracyte, Inc. is a leading company in the field of genomic diagnostics in the USA and abroad. The company was previously known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was registered in 2006, with headquarters located in South San Francisco, California. Veracyte, Inc. conducts a series of genomic tests for the detection of cancer and idiopathic pulmonary fibrosis in a CLIA-certified laboratory. The company uses advanced scientific methods such as whole transcriptome RNA sequencing and machine learning to develop tests and optimize analysis results.
What sector is Veracyte in?
Veracyte is in the Healthcare sector
What industry is Veracyte in?
Veracyte is in the Diagnostics & Research industry
What country is Veracyte from?
Veracyte is headquartered in United States
When did Veracyte go public?
Veracyte initial public offering (IPO) was on 30 October 2013
What is Veracyte website?
https://www.veracyte.com
Is Veracyte in the S&P 500?
No, Veracyte is not included in the S&P 500 index
Is Veracyte in the NASDAQ 100?
No, Veracyte is not included in the NASDAQ 100 index
Is Veracyte in the Dow Jones?
No, Veracyte is not included in the Dow Jones index
When was Veracyte the previous earnings report?
No data
When does Veracyte earnings report?
The next expected earnings date for Veracyte is 06 November 2024